Last Price
10.75
Today's Change
+0.10 (0.93%)
Day's Change
10.63 - 10.97
Trading Volume
114,358
Market Cap
1 Billion
Shares Outstanding
109 Million
Avg Volume
866,560
Avg Price (50 Days)
9.80
Avg Price (200 Days)
7.61
PE Ratio
-4.32
EPS
-2.49
Earnings Announcement
31-Oct-2024
Previous Close
10.65
Open
10.95
Day's Range
10.635 - 10.97
Year Range
3.67 - 12.14
Trading Volume
114,358
1 Day Change
0.94%
5 Day Change
-1.92%
1 Month Change
5.60%
3 Month Change
20.92%
6 Month Change
68.23%
Ytd Change
72.28%
1 Year Change
7.82%
3 Year Change
24.85%
5 Year Change
54.45%
10 Year Change
3.37%
Max Change
3.37%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.